Investor Presentation: First Nine Months of 2020
121
Investor presentation
First nine months of 2020
Novo Nordisk offers affordability programmes to increase
support to patients inside and outside the system
Continue
offering
Opera-
tionalise
Increase support for patients inside the
insurance system
Supporting Affordable Patient Access
~USD18 billion in access rebates, discounts and fees¹
>USD200 million in co-pay assistance programmes¹
Follow-on brand
insulin²
List price discount of
50% of NovoLogⓇ and
NovoLog® Mix
Safety net for those
patients inside and
outside the system
IRS Preventive Benefit
Change
.
Timing: Immediate, impact
starting 2021
CIGNA/ESI partnering on
benefit design
Expand support for patients outside
the system
Patient Assistance Program
PAP: ~50,000 patients receive free insulin¹
• Added Ozempic®, XultophyⓇ and Rybelsus®
Insulin Savings Programme²
.
.
USD99 for up to 3 vials or 2 boxes of pens
Any combination of NNI analog insulins
Affordable Human Insulin Option²
Novo Nordisk human insulin available for about USD25/vial at national pharmacies, including
Walmart and CVS
An estimated 500,000 accessing Novo Nordisk human insulin through these partnerships
An immediate, one-time insulin supply option available for people facing acute need
1 Based on full year 2010 numbers; 2 Available from Novo Nordisk Pharma, Inc., a Novo Nordisk A/S company
2 Initiatives effective as of January 2020
Novo NordiskⓇView entire presentation